References
- Van PoppelHBaertLThe present role of estramustine phosphate in advanced prostate cancerProg Clin Biol Res19913703233411924466
- DaponteDSylvesterRDe PauwMChange in white cell count during treatment of advanced cancer of the prostate with estramustine phosphate and with stilboestrolBr J Urol1983554084126349745
- TannockIFde WitRBerryWRDocetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancerN Engl J Med2004351151502151215470213
- GrangerJMKontoyiannisDPEtiology and outcome of extreme leukocytosis in 758 nonhematologic cancer patients: a retrospective, single-institution studyCancer2009115173919392319551882
- KasugaIMakinoSKiyokawaHKatohHEbiharaYOhyashikiKTumor-related leukocytosis is linked with poor prognosis in patients with lung carcinomaCancer20019292399240511745296
- SavareseDMValinskiHQuesenberryPExpression and function of colony-stimulating factors and their receptors in human prostate carcinoma cell linesProstate19983480919465939
- MountfordJCBunceCMHughesSVEstrone potentiates myeloid cell differentiation: a role for 17 beta-hydroxysteroid dehydrogenase in modulating hemopoiesisExp Hematol199927345146010089907
- DietschVKalfGFHazelBAInduction of granulocytic differentiation in myeloblasts by 17-beta-estradiol involves the leukotriene D4 receptorRecept Signal Transduct1996663759015862
- PetrylakDPTangenCMHussainMHDocetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancerN Engl J Med20043511513152015470214
- FizaziKLe MaitreAHudesGAddition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient dataLancet Oncol20078994100017942366